2020 Guide to Patient Support Services

Boehringer Ingelheim

Boehringer Ingelheim’s Gilotrif Patient Services includes a range of programs and services offered through the company’s Solutions Plus program. This program provides support, education, and reimbursement services to patients who are prescribed Gilotrif (afatinib), as well as to their providers.

Gilotrif is a tyrosine kinase inhibitor indicated as the first-line treatment of patients with metastatic non–small-cell lung cancer (NSCLC) with nonresistant epidermal growth factor receptor mutations, as detected by an FDA-­approved test, as well as for the treatment of patients with metastatic squamous NSCLC that progresses after platinum-based chemotherapy (Table).

GILOTRIF SOLUTIONS PLUS

Gilotrif’s Solutions Plus program offers a comprehensive set of services, including the Co-pay Assistance Program and the Boehringer Ingelheim Cares Foundation. These programs may offer patients access to Gilotrif through help with insurance coverage and reimbursement solutions, copay assistance, and free medication.

The Reimbursement and Access Managers program offers reimbursement specialists who can investigate and verify coverage for patients within 2 business days, communicate prior authorization requirements, and assist with the reimbursement process for Gilotrif.

Patients enrolled in Solutions Plus can also sign up for the Nurse Support Program to have dedicated oncology-trained nurses call the patient and help with the first weeks of ­Gilotrif treatment.

The Solutions Plus assistance programs differ in structure and eligibility based on the patient’s insurance and offer assistance for commercially insured, government-insured, and uninsured patients.

Boehringer Ingelheim Cares Foundation

For government-insured patients, Gilotrif Solutions Plus connects patients with alternative independent funding support programs to help offset the cost of copays, coinsurance, or other treatment-related expenses.

For uninsured or underinsured patients with Medicare, the Boehringer Ingelheim Cares Foundation provides free medication if financial assistance from other foundations is denied.

ELIGIBILITY

Co-pay Assistance Program

Eligible, commercially insured patients who are enrolled in this program pay a $0 copay monthly for Gilotrif. This program has no income eligibility or benefit limit requirements.

Boehringer Ingelheim Cares Foundation

This program offers free Gilotrif to patients who meet the eligibility criteria. To qualify for this program, patients must:

  • Be a US resident aged ≥18 years
  • Not be eligible for prescription drug assistance through Medicare, Medicaid, Medicare Part D, or private insurance. Patients under Medicare Part D who cannot afford Gilotrif may be eligible to enroll, as long as they meet other eligibility criteria and do not have any other prescription drug coverage.

APPLICATION & ENROLLMENT

Solutions Plus

A completed enrollment form must be faxed to 866-240-4556. A prescription for Gilotrif and a signed patient authorization form must also be submitted for processing. For more information on the enrollment process, call Solutions Plus at 877-814-3915. Solutions Plus contacts the patient to confirm enrollment and insurance benefits and to determine financial support needs.

Boehringer Ingelheim Cares Foundation

Applications must be faxed to 866-851-2827 from a prescriber’s facility. An original valid prescription for Gilotrif signed by a physician must be submitted for processing with the application form, ­documentation of the patient’s ­income, and any other applicable documents.

For more information on this program, call 800-556-8317.

TABLE BOEHRINGER INGELHEIM ONCOLOGY DRUG

Drug
Indications
Patient support programs

Drug
Gilotrif (afatinib)
Indications
First-line treatment of metastatic NSCLC with nonresistant EGFR mutations, as detected by an FDA-approved test; metastatic squamous NSCLC progressing after platinum-based chemotherapy
Patient support programs

EGFR indicates epidermal growth factor receptor; NSCLC, non–small-cell lung cancer.

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: